Comprehensive Cancer and Sarah Cannon Research Institute Partnership Expanding Access to Cutting-Edge Cancer Trials in Las Vegas
Las Vegas (MAY 8, 2026) – Comprehensive Cancer Centers (Comprehensive), through its affiliation with The US Oncology Network (The Network), is expanding its community-based clinical trials by collaborating with Sarah Cannon Research Institute (SCRI), one of the world’s leading oncology research organizations conducting community-based clinical trials. This collaboration will be known as “SCRI at Comprehensive Cancer Centers” and will expand access to innovative cancer treatments for patients across Southern Nevada.
Since its inception, SCRI has conducted more than 900 first-in-human trials and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA in the past decade. Through this collaboration, SCRI at Comprehensive will provide increased opportunities for patients to enroll in groundbreaking clinical trials—bringing world-class research directly into the community.
“With more than 30 years of experience bringing clinical trials to Southern Nevada, our collaboration with Sarah Cannon Research Institute represents a meaningful step forward in expanding access to innovative cancer treatments for patients in our community,” said Lisa Santwer, executive director of Comprehensive. “For decades, our focus has been on delivering advanced, compassionate care close to home. This collaboration strengthens that commitment by broadening access to clinical trials that have the potential to make a real difference in the lives of patients.”
The collaboration with SCRI offers several advantages for cancer patients:
- Greater Treatment Options: Eligible patients will have access to a wider range of clinical trials, offering options based on their individualized treatment plan.
- Access to Cutting-Edge Therapies: Eligible patients will have the opportunity to participate in trials evaluating the latest advancements in cancer research.
- Advanced Clinical Trial Matching: Comprehensive will leverage SCRI’s Personalized Medicine Team and Genospace, a highly specific trial matching technology that uses clinical and genetic data to help identify individualized trial opportunities for patients.
“This collaboration reflects the power of community based clinical research to transform patient care,” said Dee Anna Smith, CEO of SCRI. “Together, we are deepening a shared commitment to deliver innovative clinical trials within Nevada communities —expanding patient access and advancing the future of cancer care close to home.”
With local roots dating to 1974, Comprehensive has grown alongside Southern Nevada, evolving into one of the region’s most established oncology providers. The practice was built on the idea of bringing advanced cancer care into the community, uniting specialties and services under one coordinated model. Today, its physicians work closely with leading national research networks and institutions, helping translate breakthrough science into accessible treatment options for local patients. That longstanding emphasis on research-driven care has allowed Comprehensive to play a role in the development of more than 120 FDA-approved therapies.
This relationship between Comprehensive and SCRI highlights Comprehensive’s dedication to providing the most advanced, personalized cancer care close to home.
About Comprehensive Cancer Centers
Comprehensive Cancer Centers is an award-winning multi-specialty practice comprising medical oncology, hematology, radiation oncology, breast surgery, pulmonary services, cancer genetic counseling clinical research and other infusion services, with treatment centers and offices throughout Southern Nevada. For more than 50 years, the practice has provided oncology services to patients in and out of state with a specialized physician and nursing staff. Comprehensive, an affiliate of The US Oncology Network, offers state-of-the-art technologies, latest advancements in cancer treatment and groundbreaking clinical research trials. The practice participates in more than 150 Phase I, Phase II and Phase III clinical research studies each year and has played a role in developing more than 120 FDA-approved cancer therapies.
About Sarah Cannon Research Institute (SCRI)
Sarah Cannon Research Institute (SCRI) is one of the world’s leading oncology research organizations conducting community-based clinical trials. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. It has conducted more than 900 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA in the past decade. SCRI’s research network brings together approximately 1,500 oncology physicians who provide access to clinical trials in SCRI’s research network of over 200 locations in more than 20 states across the U.S. Visit SCRI.com to learn more.